Clinical Trial Update: Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pegilodecakin (LY3500518) with nivolumab versus nivolumab alone as second-line therapy in metastatic non-small cell lung cancer; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pegilodecakin (pegilodecakin)
• nivolumab (nivolumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-09-11